Generate Investment Management Ltd Invests $7.47 Million in Thermo Fisher Scientific Inc. $TMO

Generate Investment Management Ltd acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 15,403 shares of the medical research company’s stock, valued at approximately $7,471,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Forefront Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 52.9% in the third quarter. Forefront Wealth Partners LLC now owns 1,387 shares of the medical research company’s stock valued at $673,000 after buying an additional 480 shares during the last quarter. Ascent Group LLC raised its holdings in Thermo Fisher Scientific by 39.8% in the 3rd quarter. Ascent Group LLC now owns 10,963 shares of the medical research company’s stock valued at $5,317,000 after acquiring an additional 3,119 shares during the last quarter. Great Diamond Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 5.5% during the 3rd quarter. Great Diamond Partners LLC now owns 979 shares of the medical research company’s stock worth $475,000 after purchasing an additional 51 shares during the period. Baron Wealth Management LLC grew its position in shares of Thermo Fisher Scientific by 12.0% in the third quarter. Baron Wealth Management LLC now owns 718 shares of the medical research company’s stock valued at $348,000 after purchasing an additional 77 shares during the period. Finally, Sivia Capital Partners LLC purchased a new position in Thermo Fisher Scientific during the third quarter worth about $239,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research analyst reports. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, October 14th. The Goldman Sachs Group assumed coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, December 9th. They set a “buy” rating and a $685.00 price objective for the company. Argus increased their target price on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Finally, Evercore ISI upped their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $616.60.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 17,104 shares of the company’s stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $573.54, for a total value of $9,809,828.16. Following the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at $65,247,057.48. This represents a 13.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Lisa P. Britt sold 10,225 shares of Thermo Fisher Scientific stock in a transaction on Friday, November 7th. The stock was sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the sale, the vice president owned 14,145 shares of the company’s stock, valued at approximately $8,085,564.90. This trade represents a 41.96% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 149,271 shares of company stock valued at $86,507,282. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $583.52 on Wednesday. The company has a market capitalization of $219.23 billion, a price-to-earnings ratio of 33.71, a PEG ratio of 4.16 and a beta of 0.90. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The business has a 50-day moving average of $575.23 and a 200-day moving average of $506.59.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the prior year, the business earned $5.28 EPS. Thermo Fisher Scientific’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its board has approved a share buyback program on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.